Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.T. J. de Vries, G N van Muijen, D. J. Ruiter et al.|PubMed|1997Cited by 191
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.T. J. de Vries, G N van Muijen, M. Denijn et al.|PubMed|1994Cited by 149
Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative GroupT. J. de Vries, Dirk J. Ruiter, K Hou-Jensen et al.|The Journal of Pathology|2001Cited by 108
Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCRT. J. de Vries, Goos N.P. van Muijen, Th. Wobbes et al.|British Journal of Cancer|1999Cited by 78
Decreased expression of both the low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression.T. J. de Vries, G N van Muijen, Jan H. Verheijen et al.|PubMed|1996Cited by 48